Table 1. Clinicopathological characteristics and levels of inflammatory response markers of 176 patients with stage III NSCLC.
| Variable | No. of patients (%)/median (range) |
|---|---|
| Age (years) | |
| ≤60 | 68 (38.6) |
| >60 | 108 (61.4) |
| Sex | |
| Male | 157 (89.2) |
| Female | 19 (10.8) |
| Smoking status | |
| Ever | 123 (69.9) |
| Never | 53 (30.1) |
| Histological type | |
| LUSC | 65 (36.9) |
| LUAD | 87 (49.4) |
| NOS | 24 (13.6) |
| TNM stage | |
| IIIA | 57 (32.4) |
| IIIB | 97 (55.1) |
| IIIC | 22 (12.5) |
| Treatment | |
| CCRT | 32 (18.2) |
| SCRT | 144 (81.8) |
| Neutrophils, ×109/L | 4.65 (0.10–18.67) |
| Monocytes, ×109/L | 0.49 (0–2.01) |
| Lymphocytes, ×109/L | 1.74 (0.28–4.06) |
| NLR | 2.80 (0.10–35.20) |
| SIRI | 1.35 (0–25.00) |
*, P<0.05 is considered significant. NSCLC, non-small cell lung cancer; LUSC, lung squamous carcinoma; LUAD, lung adenocarcinoma; NOS, not otherwise specified; TNM, tumor node metastasis; CCRT, concurrent chemoradiotherapy; SCRT, Sequential chemoradiotherapy; NLR, neutrophil-to-lymphocyte ratio; SIRI, systemic inflammation response index.